You are here

Vascepa

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Yahoo/Benzinga

acute coronary syndrome

clinical trials

Flag link:

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

Fierce Pharma

Flag link:

Struggling Amarin jousts with activist investor Sarissa as board vote nears

Struggling Amarin jousts with activist investor Sarissa as board vote nears

Fierce Pharma

Flag link:

Why Amarin Stock Was a Winner Today

Why Amarin Stock Was a Winner Today

Motley Fool

Flag link:

Amarin stands behind Vascepa after new analysis raises questions about its efficacy

Amarin stands behind Vascepa after new analysis raises questions about its efficacy

Fierce Pharma

Flag link:

Amarin turns to job cuts as generics challenge its heart pill

Amarin turns to job cuts as generics challenge its heart pill

BioPharma Dive

Flag link:

With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

With sales sagging, Amarin sees progress on new Vascepa digital effort in the US

Fierce Pharma

digital marketing

Flag link:

Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy

Faced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy

Fierce Pharma

Flag link:

ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim

ESC: Amarin touts Vascepa's ability to reduce repeat heart problems as it fights generic with 'skinny label' claim

Fierce Pharma

Flag link:

Amarin's Vascepa patent defense ends in a loss at the Supreme Court

Amarin's Vascepa patent defense ends in a loss at the Supreme Court

Fierce Pharma

Flag link:

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

Fierce Pharma

Flag link:

The top 10 drugs losing U.S. exclusivity in 2021

The top 10 drugs losing U.S. exclusivity in 2021

Fierce Pharma

Flag link:

Amarin vs. the Generics: Who Will Win?

Amarin vs. the Generics: Who Will Win?

Motley Fool

Flag link:

AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts

AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts

Fierce Pharma

Flag link:

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire

Endpoints

Flag link:

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Amarin Patent Appeal Is a Coin Toss With Billions on the Line

Yahoo/Bloomberg

Flag link:

ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment

ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment

Fierce Pharma

arterial plaque

Flag link:

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Fierce Pharma

Flag link:

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Motley Fool

Flag link:

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

Fierce Pharma

Flag link:

Pages